|
 |
Noms commerciaux |
|
|
Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires
|
|
Acetaflur |
Mexique |
|
Asoleudox |
Mexique |
|
Beneflur |
Espagne, Mexique |
|
Fludabin |
Pérou |
|
Fludacel |
Inde, Pérou |
|
Fludakebir |
Pérou |
|
Fludalym |
Turquie |
|
Fludara |
Allemagne, Arabie Saoudite, Autriche, Belgique, Chili, Colombie, Danemark, Egypte, Etats Unis d’Amérique, Finlande, France, Grande Bretagne, Hongrie, Inde, Iran, Irlande, Italie, Luxembourg, Malaisie, Nouvelle Zélande, Pays bas, Pologne, Portugal, Roumanie, Suède, Suisse, Vénézuela |
|
Fludarabin |
Islande, Italie, Norvège, Suède, Suisse |
|
Fludarabina |
Argentine, Colombie, Espagne, Pérou, Roumanie |
|
Fludarabine |
Belgique, Canada, Etats Unis d’Amérique, Iran, Norvège, Nouvelle Zélande, Suisse |
|
Fludarin |
Inde |
|
Fludarosa |
Argentine |
|
Forclina |
Pérou |
|
Ludabina |
Chili, Colombie |
|
Mepredin |
Pérou |
|
Naprobin |
Inde |
|
Neoflubin |
Iran |
|
|
 |
 |
Bibliographie : Fludarabine phosphate |
|
|
Type |
Source |
| 3 |
Revue |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 81 |
Revue |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Revue |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
Revue |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
Revue |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Revue |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
Revue |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 307 |
Revue |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 492 |
Revue |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 905 |
Revue |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 1410 |
Revue |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1423 |
Revue |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 2344 |
Laboratoire |
Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution.
Ebewe Pharma 2009 |
| 3306 |
Revue |
Trittler R.
New stability studies for fludarabine according to the European Pharmacopoeia 7.0
EJOP 2012 ; 6, 1: 1-2. |
| 3595 |
Laboratoire |
Aciclovir - Summary of Product Characteristics
Hospira 2009 |
| 3604 |
Laboratoire |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012 |
| 3637 |
Laboratoire |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014 |
| 3644 |
Laboratoire |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3670 |
Revue |
Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30. |
| 3838 |
Laboratoire |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 4398 |
Revue |
Smith E. K., Shergold J.A., McWhinney B.C.
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush.
J Pharm Pract and Res 2020 |
|
|
